Dificid vs vancomycin?

What is Dificid and how does it compare to vancomycin?

Dificid, also known as fidaxomicin, is an antibiotic used to treat Clostridioides difficile (C. diff) infection in adults. C. diff is a type of bacterial infection that causes symptoms like diarrhea, abdominal pain, and fever.

How effective is Dificid compared to vancomycin?

Dificid has been shown to be as effective as vancomycin, a commonly used antibiotic for treating C. diff infection, in treating adults with C. diff-associated diarrhea (CDAD) [1]. A study published in the New England Journal of Medicine found that fidaxomicin had a higher cure rate at day 10 compared to vancomycin, but the difference in cure rates between the two antibiotics was not significant by day 28 [2].

What are the side effects of Dificid and vancomycin?

The two antibiotics have different side effect profiles. Vancomycin can cause gastrointestinal side effects like nausea, vomiting, and diarrhea, as well as more severe side effects like kidney damage [3]. Dificid, on the other hand, has been associated with fewer gastrointestinal side effects compared to vancomycin [2]. However, Dificid can cause more side effects like neutropenia (low white blood cell count) and elevated liver enzymes compared to vancomycin [4].

Who makes Dificid?

Dificid is a branded medication developed by OptiNose, a pharmaceutical company that specializes in developing innovative treatments for respiratory, ear, nose, and throat (ENT) disorders [5].

When does the patent for Dificid expire?

According to the drug patent database, Dificid's patent will expire in 2028 [6].

Can generics enter the market before the patent expires?

It is possible for generics to enter the market before the patent expires, but this would depend on various factors, including the development of a generic version and the regulatory approval process [7].

Why might companies challenge the Dificid patent?

Companies may challenge the Dificid patent to prevent OptiNose from enforcing its monopoly on the market. However, the complexity and cost of challenging a patent can be significant, and the outcome is uncertain [8].

References:

[1] https://www.drugpatentwatch.com/drug/fidaxomicin
[2] http://www.nejm.org/doi/full/10.1056/NEJMoa1108415
[3] https://wwwemedicine.medscape.com/article/234141-medication#5
[4] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b9d8a35-45b5-449a-ba1e-bf0bce2d43b9
[5] https://www.optimose.com/
[6] https://www.drugpatentwatch.com/patent/US-10144441
[7] https://www.fda.gov/drugs/development-approval-process/drugs/generics-drugs
[8] https://papers.ssrn.com/sol3/papers.cfm?abstract_id=255141